Hypomagnesemia 7 (ADKH-RRAGD): A Patient Guide
At a Glance
Hypomagnesemia 7 (ADKH-RRAGD) is a rare inherited RRAGD-related disorder in which the kidneys lose magnesium and potassium. Some people also develop dilated cardiomyopathy, so ongoing kidney, heart, and genetic specialist monitoring is important.
Hypomagnesemia 7—often referred by its scientific shorthand ADKH-RRAGD—is an ultra-rare genetic condition that disrupts how your body handles vital minerals. At its core, the condition is caused by a pathogenic variant in the RRAGD gene. This gene provides instructions for a protein that helps cells sense nutrients and manage growth. Current experimental models suggest that when this gene is altered, it alters cellular signaling, which interferes with the normal function of cells, primarily in the kidneys and sometimes the heart [1].
The most consistent feature of this condition is a tubulopathy, a term for a disorder in the tiny tubes of the kidneys. In ADKH-RRAGD, these tubes fail to recycle magnesium and potassium back into the blood, instead flushing them out of the body as waste. This “electrolyte wasting” can lead to persistently low levels of magnesium and potassium, which are essential for muscle function and heart rhythm [2]. While some similar kidney disorders consistently cause massive calcium buildup in the kidneys, calcium levels in the urine can vary widely in RRAGD; some patients have normal or low calcium in their urine, while others may have excess calcium that requires individualized monitoring [3].
For some individuals, the condition also extends to the heart muscle, leading to dilated cardiomyopathy (DCM). In these cases, the heart’s main pumping chamber becomes enlarged and the muscle walls weaken, making it more difficult to circulate blood effectively. The risk and severity of heart involvement are highly variable; while some people experience severe symptoms in early childhood, others may have no heart issues at all or develop them much later in life [1]. This variability appears linked to the specific pathogenic variant a person carries [4].
Because the condition is reported in only a small number of families worldwide and affects two critical organ systems, management requires a multidisciplinary care team. This group typically includes a nephrologist (kidney specialist) to manage electrolyte replacement, a cardiologist (heart specialist) to monitor heart strength, and a medical geneticist to help navigate the implications for the patient and their family [1]. While current treatments focus on replacing lost minerals and supporting heart function, staying connected with these specialists ensures that your care is proactive and tailored to your specific clinical findings and genetic profile [3].
In this guide
6 chapters
Understanding Your Diagnosis: Hypomagnesemia 7 (ADKH-RRAGD)
Learn how Hypomagnesemia 7 (ADKH-RRAGD) affects kidney magnesium and potassium levels and why some patients develop dilated cardiomyopathy or arrhythmias.
The RRAGD Gene and Genetic Variants
Learn how RRAGD variants cause Hypomagnesemia 7, how the condition is inherited, and why genetic testing plus heart and kidney monitoring matter for families.
Kidney Symptoms and Electrolyte Management
Learn how Hypomagnesemia 7 affects kidney mineral balance, magnesium and potassium loss, supplement side effects, warning signs, and when to seek urgent care.
Cardiac Risks and Dilated Cardiomyopathy
Learn how RRAGD-related hypomagnesemia 7 can affect the heart, including dilated cardiomyopathy, warning signs, and recommended cardiac monitoring and follow-up.
Building Your Care Team and Monitoring Schedule
Learn how to build a care team and monitoring plan for hypomagnesemia 7, including kidney and heart care, blood tests, urine studies, and sick-day planning.
Experimental Treatments and Research
Learn about experimental treatments for hypomagnesemia 7, including SGLT2 inhibitors, mTOR research, clinical trials, registries, and research participation.
Common questions in this guide
What is Hypomagnesemia 7 (ADKH-RRAGD)?
Why are magnesium and potassium low in this condition?
Can Hypomagnesemia 7 cause dilated cardiomyopathy?
What treatment and monitoring does ADKH-RRAGD require?
Does everyone with RRAGD-related hypomagnesemia have high urine calcium?
Get notified when new evidence is published on hypomagnesemia 7, renal, with or without dilated cardiomyopathy.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (4)
- 1
RRAGD-Associated Autosomal Dominant Kidney Hypomagnesemia with Cardiomyopathy: A Review on the Clinical Manifestations and Therapeutic Options.
Trepiccione F, Sambri I, Ruggiero B, et al.
Kidney & blood pressure research 2024; (49(1)):637-645 doi:10.1159/000539889.
PMID: 38901414 - 2
mTOR-Activating Mutations in RRAGD Are Causative for Kidney Tubulopathy and Cardiomyopathy.
Schlingmann KP, Jouret F, Shen K, et al.
Journal of the American Society of Nephrology : JASN 2021; (32(11)):2885-2899 doi:10.1681/ASN.2021030333.
PMID: 34607910 - 3
Novel RRAGD Variants in Autosomal Dominant Kidney Hypomagnesemia and Therapeutic Perspectives.
Adella A, Jouret F, Madariaga L, et al.
Kidney international reports 2025; (10(10)):3640-3655 doi:10.1016/j.ekir.2025.07.035.
PMID: 41141537 - 4
RRAGD variants cause cardiac dysfunction in a zebrafish model.
Adella A, Tengku F, Arjona FJ, et al.
American journal of physiology. Heart and circulatory physiology 2024; (327(5)):H1187-H1197 doi:10.1152/ajpheart.00705.2023.
PMID: 39331021
This page explains RRAGD-related hypomagnesemia for informational purposes and does not replace medical advice. A nephrologist, cardiologist, and medical geneticist should interpret your results and determine your monitoring and treatment plan.